Approach to the patient with infectious colitis

Current Opinion in Gastroenterology

Volumn 28, Issue 1, 2012, Pages 39-46

  DuPont, Herbert L ^a  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bacterial diarrhea; Campylobacter; Infectious colitis; Salmonella; Shiga toxin producing E. coli; Shigella

Indexed keywords

AZITHROMYCIN; CALGRANULIN; CIPROFLOXACIN; COTRIMOXAZOLE; DIIODOHYDROXYQUIN; DILOXANIDE FUROATE; ERYTHROMYCIN; FIDAXOMICIN; GANCICLOVIR; LACTOFERRIN; LEVOFLOXACIN; METRONIDAZOLE; PAROMOMYCIN; PRAZIQUANTIL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SHIGA TOXIN; UNCLASSIFIED DRUG; VANCOMYCIN;

AEROMONAS; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTEROIDES FRAGILIS; CAMPYLOBACTER; CLOSTRIDIUM DIFFICILE; COLITIS; CYTOMEGALOVIRUS; DIARRHEA; DYSENTERY; ENTAMOEBA HISTOLYTICA; ENTEROAGGREGATIVE ESCHERICHIA COLI; ENTEROINVASIVE ESCHERICHIA COLI; EPIDEMIC; FECES CULTURE; FEVER; HUMAN; INFECTIOUS COLITIS; INTESTINE ENDOSCOPY; LEUKOCYTE; REVIEW; SALMONELLA; SCHISTOSOMA MANSONI; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGELLA; VIBRIO;

BACTERIA; BACTERIAL INFECTIONS; COLITIS; COLONOSCOPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; INTESTINAL MUCOSA; WORLD HEALTH;

EID: 84857061514     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32834d3208     Document Type: Review

References (29)

1. Gould LH, Bopp C, Strockbine N, et al. Recommendations for diagnosis of shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep 2009; 58:1-14.
2. Cao J, Liu WJ, Xu XY, Zou XP. Endoscopic findings and clinicopathologic characteristics of colonic schistosomiasis: a report of 46 cases. World J Gastroenterol 2010; 16:723-727. The endoscopic findings of 46 patients with colonic schistosomiasis are described.
3. DuPont HL. Clinical practice. Bacterial diarrhea. N Engl J Med 2009; 361:1560-1569. This review summarizes the burden of the various bacterial causes of diarrhea and colitis. It furthermore provides recommendations on diagnosis and therapy.
4. Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology 2009; 136:1899-1912.
5. Kassenborg HD, Smith KE, Vugia DJ, et al. Fluoroquinolone-resistant Campylobacter infections: eating poultry outside of the home and foreign travel are risk factors. Clin Infect Dis 2004; 38 (Suppl 3):S279-S284. (Pubitemid 38553335)
6. Nandy S,Mitra U, Rajendran K, et al. Subtype prevalence, plasmid profiles and growing fluoroquinolone resistance in Shigella from Kolkata, India (2001- 2007): a hospital-based study. Trop Med Int Health 2010; 15:1499-1507. The growing problem of fluoroquinolone resistance is making therapy of bacterial diarrhea more difficult.
7. Howie RL, Folster JP, Bowen A, et al. Reduced azithromycin susceptibility in Shigella sonnei, United States. Microb Drug Resist 2010; 16:245-248. Emergence of azithromycin resistance among the bacterial enteropathogens will complicate therapy because this agent is uniquely effective against strains of Shigella and Campylobacter, the two most important causes of acute dysentery in the USA.
8. Ohara T, Kojio S, Taneike I, et al. Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response. Antimicrob Agents Chemother 2002; 46:3478-3483. (Pubitemid 35192914)
9. Ochoa TJ, Chen J, Walker CM, et al. Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli. Antimicrob Agents Chemother 2007; 51:2837-2841. (Pubitemid 47206219)
10. Jess T, Simonsen J, Nielsen NM, et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut 2011; 60:318-324. This very large Danish study fails to show an association between Salmonella and Campylobacter infection and subsequent development of inflammatory bowel disease.
11. Brauner A, Brandt L, Frisan T, et al. Is there a risk of cancer development after Campylobacter infection? Scand J Gastroenterol 2010; 45:893-897. A very large Swedish study failed to show a relationship between Campylobacter infection and subsequent development of cancers of the gastrointestinal tract.
12. Toprak NU, Yagci A, Gulluoglu BM, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect 2006; 12:782-786. (Pubitemid 43983804)
13. Sears CL, Islam S, Saha A, et al. Association of enterotoxigenic Bacteroides fragilis infection with inflammatory diarrhea. Clin Infect Dis 2008; 47:797-803.
14. Jiang ZD, DuPont HL, Brown EL, et al. Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol 2010; 48:1417-1419. The study demonstrated that travelers' diarrhea cases occurring in Mexico, Guatemala, and India were caused by enterotoxigenic B. fragilis and Arcobacter butzleri in 7% and 8%, respectively. Travelers' diarrhea is known to be caused by pathogens also commonly seen in local children with diarrhea suggesting the two organisms will be important in that setting.
15. Kawaratani H, Tsujimoto T, Toyohara M, et al. Pseudomembranous colitis complicating ulcerative colitis. Dig Endosc 2010; 22:373-375. The possibility of CDI should be considered in patients with IBD when enteric symptoms worsen during the course of therapy with antibiotics or immunosuppressive treatments. CDI is further suggested when pseudomembranous colitis complicates IBD.
16. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and clostridium difficile infection. Clin Gastroenterol Hepatol 2009; 7:981-987.
17. Rizzo M, Mansueto P, Cabibi D, et al. A case of bowel schistosomiasis not adhering to endoscopic findings. World J Gastroenterol 2005; 11:7044-7047. (Pubitemid 43126069)
18. Lin YH, Yeh CJ, Chen YJ, et al. Recurrent cytomegalovirus colitis with megacolon in an immunocompetent elderly man. J Med Virol 2010; 82:638-641.
19. Kim CH, Bahng S, Kang KJ, et al. Cytomegalovirus colitis in patients without inflammatory bowel disease: a single center study. Scand J Gastroenterol 2010; 45:1295-1301. CMV infection was diagnosed by colonoscopy in 43 patients with CMV colitis. Many of the patients had spontaneous recovery while biopsies were being evaluated.
20. Talan D, Moran GJ, Newdow M, et al. Etiology of bloody diarrhea among patients presenting to United States emergency departments: prevalence of Escherichia coli O157:H7 and other enteropathogens. Clin Infect Dis 2001; 32:573-580. (Pubitemid 32564997)
21. Harris JC, DuPont HL, Hornick RB. Fecal leukocytes in diarrheal illness. Ann Intern Med 1972; 76:697-703.
22. van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic metaanalysis. BMJ 2010; 341:c3369. Fecal calprotectin is a useful screening test to determine who should be evaluated for IBD by endoscopy.
23. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SESCD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105:162-169.
24. Shastri YM, Bergis D, Povse N, et al. Prospective multicenter study evaluating fecal calprotectin in adult acute bacterial diarrhea. Am J Med 2008; 121: 1099-1106.
25. Sykora J, Siala K, Huml M, et al. Evaluation of faecal calprotectin as a valuable noninvasive marker in distinguishing gut pathogens in young children with acute gastroenteritis. Acta Paediatr 2010; 99:1389-1395.
26. DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525-1528.
27. Koo HL, Koo DC, Musher DM, DuPont HL. Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis 2009; 48:598-605. A thorough evaluation of the literature and post-marking information from the company suggested that the antimotility agent loperamide was not associated with worsening of CDI if the patients were also treated with anti-CDI antibiotics.
28. Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993; 118:582-586. (Pubitemid 23102691)
29. Nelson JM, Griffin PM, Jones TF, et al. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites. Clin Infect Dis 2011; 52:1130-1132